Tag Archive for: Amneal Pharmaceuticals

Crexont was previously rejected by the regulator in June 2023, citing insufficient safety data. However, Amneal Pharmaceuticals’ resubmission included findings from a healthy volunteer study.

The FDA will close the month of June with four target action dates, including one for an investigational gene therapy for a rare disease and another for an already top-selling eye disease treatment.